Jazz to Acquire Redx Global Rights to KRAS Inhibitor Program

 Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales

Preclinical program expands Jazz's pipeline of targeted oncology therapies

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-enters-definitive-agreement-with-redx-pharma-to-acquire-global-rights-to-kras-inhibitor-program-302055488.html